

November 4, 2005

Public Relations
Ono Pharmaceutical Co., Ltd.
Tel: +81-6-6263-5670
Fax: +81-6-6263-2950

**Ono Entered Into Drug Discovery Agreement on Kinases
with Array BioPharma Inc.**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Takashi Iwai) announced today that the company signed a drug discovery agreement with Array BioPharma Inc. (Colorado, USA; CEO: Robert E. Conway).

Under the arrangement, the parties will seek small molecule drug candidates targeting a series of kinases selected by Ono. Ono will have the sole responsibility for clinical development and commercialization of resulting products. In addition to research funding, Array will receive research and development milestone payments and royalties based on sales of the resulting products.

***Comments from Array**

“We are delighted to be initiating this multi-year collaboration with Ono,” said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array. “We view Ono’s interest in partnering with Array as further validation of our ability to create high quality clinical candidates.”

***Comments from Ono**

“We dedicate ourselves on creating innovative medicines,” said Kigen Kondo, Ph.D., Executive Director of Research Headquarters, Ono. “We are very much pleased about this collaborative arrangement with Array, a biopharmaceutical company with excellent state-of-the-art technologies, to create drug candidates modulating our selected new targets.”

(Reference)

Kinases

Protein phosphorylation is catalyzed by specific enzymes called kinases and is an important regulatory event in the pathways modulating the cellular functions. There are many types of kinases and it is believed that kinases are involved in various diseases.

About Array BioPharma

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.